For Research Use Only. Not for use in diagnostic procedures.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of AKR1C4 cdna clone vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

37,067 Da

aldo-keto reductase family 1 member C4

aldo-keto reductase family 1 member C4

Aldo-keto reductase family 1 member C4

CHDR; CDR; DD-4; DD4??[Similar Products]

AK1C4_HUMAN

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the bioreduction of chlordecone, a toxic organochlorine pesticide, to chlordecone alcohol in liver. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. [provided by RefSeq, Jul 2008]

AKR1C4: Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha- androstan-3-alpha,17-beta-diol (3-alpha-diol). Also has some 20- alpha-hydroxysteroid dehydrogenase activity. The biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leads to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route. Defects in AKR1C4 are a cause of 46,XY sex reversal type 8 (SRXY8). A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females. AKR1C4 mutations may act as modifier of disease severity in SRXY8 patients. A splicing mutation resulting in loss of exon 2 has been found in affected individuals also carrying mutation Val-79 in AKR1C2 (PubMed:21802064). Belongs to the aldo/keto reductase family.

Protein type: EC 1.1.1.357; Lipid Metabolism - C21-steroid hormone; Lipid Metabolism - androgen and estrogen; Xenobiotic Metabolism - metabolism by cytochrome P450; Oxidoreductase; Lipid Metabolism - primary bile acid biosynthesis; EC 1.1.1.225

Chromosomal Location of Human Ortholog: 10p15.1

Cellular Component: cytoplasm; cytosol

Molecular Function: 3(or 17)-alpha-hydroxysteroid dehydrogenase activity; aldo-keto reductase activity; bile acid transmembrane transporter activity; electron carrier activity; oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor; retinal dehydrogenase activity

Biological Process: androgen metabolic process; bile acid and bile salt transport; bile acid biosynthetic process; retinoid metabolic process; steroid metabolic process

Disease: 46,xy Sex Reversal 8

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.